Coronavirus

Yes, some people really like seeing click-bits in the news that “Ethanol can improve one’s health” (not), and “Chocolate is wonder medicine” (but only if you eat over 12 pounds of it each day, etc). Do you find yourself able to smoke/vape when trying shake-off a nasty Rhinovirus or Influenza ? I generally do not. I can assure you that SARS-CoV-2 is not something that folks would be well advised to give any sort of chance to take hold in one’s (particularly lower portions of the) lungs. That PG, VG, and Nicotine (not to mention various flavoring molecules) are fully capable of irritating (and thus compromising) pulmonary immune-functions and health is only denied by those having some “vested interests” in those practices. And aging “vapers” who (previously, or concurrently) smoked for long periods of time are especially and particularly vulnerable to various compromised pulmonary conditions. (I would) take nothing for granted.

.

That is (perhaps) a bit “lightweight” (on the alkaloid-scale) for the situation. I myself would hope for somewhat (if not much more) more efficacious Mu-receptor agonists, that will here remain unnamed.
:innocent:

1 Like

I agree. No one should come away from reading any of those reports of nicotine/pg use as a safe pass from contracting the virus or lessened effects from it. But it would be an incredible “discovery” if any of the science eventually backs it up. A vaper can only dream at this point. :thinking:

3 Likes

Good to hear that you have a fine mind (which I have already surmised), and that it is “screwed on straight”. Jest remember that CNN = UN = Bad Santa, and COVID-19 = 5G = Zinc Flouride, and you should do just fine in the coming “Red Night of Dunning-Kruger”. Whatever you do, do not let them extract the Gold from any dental fillings ! You’ll need that precious element to “beam up” to Mothership !

BTW, I recently noticed that my iconic (and uber-prescient) in-law “Debbie Downer” is “back in town”.
:clown_face:

(Nature, April 28, 2020):

The race for coronavirus vaccines: a graphical guide -
Eight ways in which scientists hope to provide immunity to SARS-CoV-2

(Josh Bloom, ACSH, April 30, 2020):

Remdesivir 1st Controlled Trial Is No Cause For Celebration -
After months of speculation, the results of the first placebo-controlled trial of remdesivir are out.
The drug does help people with COVID-19 disease, but it’s nothing to get excited about. Here’s why.

Unfortunately, based on this first trial, it is doubtful that remdesivir will be the “magic pill” people have been hoping for. Remdesivir is not something people will be able to swallow at the first sign of COVID disease and feel better. It’s not a pill and it’s not magical either.

Bad news :frowning: Let’s hope bemcentinib gets better results! That is a pill and is said to prevent virus replication :slight_smile: Man, I hope it is effective!

2 Likes

That would be nice. Here’s hoping!

1 Like

So does anyone have a source for testing numbers outside the US? I see lots of US tested numbers but can’t find other countries. I’m trying, like many, to get an understanding of the scope of the virus and maybe understand why the US is so far above other countries in cases. Just about all I’m sure of is China’s numbers are intentionally false.

1 Like

(The New Yorker, April 29, 2020):

What We Don’t Know About the Coronavirus

(The New Yorker, April 23, 2020):

The Challenges of Post-COVID-19 Care

New IMHE Model Projected Total Released Today: 161,321 US deaths (by Aug 4, 2020)

Looks like no @anon70102222.

Their numbers are a complete and total joke.

1 Like

Haven’t you heard? No more than 100,000 in the US will die from the pandemic

Oh, and we (or rather the US) will have a vaccine ready this year :stuck_out_tongue:

2 Likes

California is one of the last states I’d have expected to read this about.

2 Likes

COVID - Coronavirus Statistics - Worldometer - last column

2 Likes

(AAAS Science, May 1, 2020):

SARS-CoV-2 productively infects human gut enterocytes

The virus severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) can cause coronavirus disease 2019 (COVID-19), an influenza-like disease that is primarily thought to infect the lungs with transmission via the respiratory route. However, clinical evidence suggests that the intestine may present another viral target organ. Indeed, the SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) is highly expressed on differentiated enterocytes. In human small intestinal organoids (hSIOs), enterocytes were readily infected by SARS-CoV and SARS-CoV-2 as demonstrated by confocal- and electron-microscopy. Consequently, significant titers of infectious viral particles were detected. mRNA expression analysis revealed strong induction of a generic viral response program. Hence, intestinal epithelium supports SARS-CoV-2 replication, and hSIOs serve as an experimental model for coronavirus infection and biology.

.

Article about the content of the above-linked research report:

Thanks @Mikser

1 Like

Current evidence does not seem to point to aerosolization as the key route of transmission of SARS-CoV-2, and there have been reports of healthcare workers not being infected after exposure to confirmed patients despite not using airborne precautions. Detailed epidemiologic studies of outbreaks, in both healthcare and non-healthcare settings, should be carried out to determine the relative contribution of various routes of transmission and their correlation with patient-level factors.
In conclusion, in a limited number of AIIR environments, our current study involving individual COVID-19 patients not undergoing aerosol-generating procedures or oxygen supplementation suggest that SARS-CoV-2 can be shed in the air from a patient in particles sized between 1 to 4 microns. Even though particles in this size range have the potential to linger longer in the air, more data on viability and infectiousness of the virus would be required to confirm the potential airborne spread of SARS-CoV-2. Additionally, the concentrations of SARS-CoV-2 in the air and high-touch surfaces could be highest during the first week of COVID-19 illness. Further work is urgently needed to examine these findings in larger numbers and different settings to better understand the factors affecting air and surface spread of SARS-CoV-2 and inform effective infection prevention policies.

.

The (potentially somewhat) good news is that N95 type masks claim to stop up to 95% of particles and droplets down to ~0.3 Micron (although I have read that SARS-CoV-2 itself is between ~0.075 to ~0.15 Micron in size - will be re-checking regarding those listed dimensions). Perhaps somewhat reassuring.

The (very likely indeed) bad news is that the common (3M Brand) “Surgical Masks” appear to only be alleged (by 3M) to block particles/droplets larger than ~100 Microns. Seemingly close to useless. :thinking:

An important issue (and a tangible potential danger for many of those persons who are most vulnerable to SARS-CoV-2 infection) is the (significant) extent that a (properly fitted) N95 type mask impedes the inspiration/exhalation of air (thus decreasing Oxygen, and increasing Carbon Dioxide, in the lungs).

.

2 Likes

I have been looking at this demo, i don’t know how accurate the data is.

1 Like

Interesting display of details.

1 Like